UroGen Pharma (URGN) Q1 2024 Annual Earnings
URGN·Reported May 13, 2024·Before market open
UroGen Pharma reported Q1 2024 revenue of $18.8M, missed analyst consensus of $21.4M by $2.6M. Diluted EPS came in at $-0.97, missed the $-0.93 consensus by $0.04.
Revenue
$18.8Mmissed by $2.6M
Consensus: $21.4MDiluted EPS
$-0.97missed by $0.04
Consensus: $-0.93
Financial Snapshot
Trailing eight quarters through Q1 2024
Q1 2024 Earnings FAQ
Common questions about UroGen Pharma's Q1 2024 earnings report.
UroGen Pharma (URGN) reported Q1 2024 earnings on May 13, 2024 before market open.
UroGen Pharma reported revenue of $18.8M and diluted EPS of $-0.97 for Q1 2024.
Revenue missed the consensus estimate of $21.4M by $2.6M. EPS missed the consensus estimate of $-0.93 by $0.04.
You can read the 10-K/A periodic report (0001437749-24-013504) directly on SEC EDGAR. The filing index links above go to sec.gov.